.png){kind=logo}
Welcome to Courtney File's Page
Courtney File
Back at it again for our 2023 Guys and Dolls Signature Event. This will be my 2nd year Co-Chairing Team Sienna and I could not be more excited. This is a cause I care very deeply about and have seen so many advancements in the 5 years I have been involved with the Cystic Fibrosis Foundation thanks to your donations and participation in our events.
My history with the CFF:
Guys and Dolls:
2022 / 2023 - Co-Chair, Team Sienna.
2021 - All Star Honoree turned Co-Chair
2019 - Committee member.
2018 - "Doll" Honoree.
Rocktoberfest:
2017 - 2019: Committee Member
Tomorrow's Leaders:
2019 - Present: Member and Recipient of the 2020 Tomorrow's Leader Award
Volunteer Work:
2017 - A Night with the Master Chef's & Guys and Dolls
2018 - Great Strides
2019 - Xtreme Hike Spring and Fall volunteer & Great Strides
I have met some of my best friends through this amazing Foundation while volunteering and raising money that is going straight to patient care and drug research and development. Here are some of the major developments that have happened since I started working with the Foundation:
2017: The Foundation launches the Lung Transplant Initiative, an effort to improve outcomes for people with CF who undergo lung transplantation.
2018: The FDA approves tezacaftor/ivacaftor (Symdeko®) combination therapy for people with CF ages 12 and older who have two copies of the F508del mutation, providing another option for people in this population, particularly individuals who cannot tolerate lumacaftor/ivacaftor (Orkambi). Later, tezacaftor/ivacaftor is approved for individuals who have a single copy of one of 26 specified mutations – regardless of their other mutation.
2018: The CF Foundation launches the Infection Research Initiative, a comprehensive, $100 million effort to improve the detection, diagnosis, treatment, and outcomes of CF-related infections
2019: The FDA approves the triple-combination modulator elexacaftor/tezacaftor/ivacaftor (Trikafta®) for people with CF ages 12 and older who have at least one copy of the F508del mutation, regardless of their other mutation. This historic breakthrough means that for the first time the majority of the CF population could eventually have a highly effective therapy for the underlying cause of their disease. The Foundation launches its Path to a Cure, a $500 million research portfolio to accelerate treatments for all people with CF, including those who do not yet have a transformative treatment for their disease.
2020: Despite the challenges brought on by the COVID-19 global pandemic, the CF Foundation funds more in research and care in 2020 than at any other time in the history of its mission.
Cystic fibrosis is a devastating genetic disease that affects the lungs and digestive system. More than ten million Americans are symptomless carriers of the defective CF gene. Advances continue to be made in finding a cure, but your help is needed now -- more than ever -- to help keep up the momentum of this life-saving research. Sixty years ago, children with CF usually did not live long enough to attend elementary school. Today, because of Foundation-supported research and care, the median survival age of people with CF is about 40. This is remarkable progress, but not good enough. We continue to lose precious lives to CF every day. To learn more about CF and the CF Foundation, visit www.cff.org. Together, we can make a difference in the lives of those with cystic fibrosis. Thank you for supporting the mission of the CF Foundation!My Passion campaigns
-
$455.00 raised
Comments